Pharmacology

Question 1

Obinutuzumab mechanism

Answer 1

Type II humanized anti-CD20 MABs

Question 2

Black box warnings for CD20 MAbs

Answer 2

• Hep B reactivation
• PML
• Infusion reactions (Rituxan)
• Severe mucocutaenous reaction (Rituxan)

Question 3

Dara SE’s

Answer 3

• infusion reactions
• myelosuppression
• ## herpes reactivation

Question 4

Tafasitamab mechaism

Answer 4

Humanized CD19 mAb that mediates B-cell lysis through apoptosis and immune effector mechanisms

Question 5

Tafastimab SE’s

Answer 5

• bone marrow suppression
• peripheral edema

Question 6

mogamulizumab mechanism

Answer 6

Humanized CCR4 mAb that results in target cell depletion through antibody-dependent cellular cytotoxicity

Question 7

mogamulizumab indication

Answer 7

mycosis fungoides/sezary syndrome

Question 8

mogamulizumab SE’s

Answer 8

• increased transplant in complications, including mortality, if administered less than 50 days before HSCT
• autoimmune toxicity (myositis, myocarditis, hepatitis, pneumonitis)

Question 9

Brentuximab vedotin mechanism

Answer 9

CD30 ADC w/ MMAE as payload

Question 10

polatuzumab vedotin mechanism

Answer 10

• CD79B ADC w/ MMAE as payload

Question 11

Inotuzumab target

Answer 11

CD22

Question 12

Inotuzumab black box warnings

Answer 12

1) hepatotoxicity/VOD
2) higher day 100 post-HSCT mortality rate

Question 13

loncastuximab mechanism

Answer 13

Humanized CD19 ADC designed to deliver tesirine to malignant cells

Question 14

Drugs that are active against BCR-ABL T3151 mutation

Answer 14

ponatinib
*asciminib

Question 15

What do IMIDS target?

Answer 15

CRBN protein (induces proteasome degradation)

Question 16

Difference in mechanism between bortezomib and carfilzomib

Answer 16

• bortezomin is reversible proteasome inhibition, carfilzomib is irreversible inhibition

Question 17

Major benefit of giving bortezomib subcutaneously

Answer 17

Less peripheral neuropathy than IV bortezomib

Question 18

What are the HDAC (histone deacytelase) inhibitors?

Answer 18

• vorinostat
• belinostat
• romidepsin

Question 19

HDAC inhibitor SE’s

Answer 19

• QTc prolongation
• infection

Question 20

pirtobrutinib unique mechanism as BTK inhibitor

Answer 20

non-covalent
*binds to wild type BTK as well as BTK harboring C481 mutations

Question 21

Gilteritinib SE’s

Answer 21

• differentiation syndrome
• prolonged QT interval

Question 22

Midostaurin SE’s

Answer 22

• increased creatinine
• mucositis
• prolonged QT intrval
• MSK pain and arthralgias

Question 23

Primary SE to know for IDH inhibitors

Answer 23

• differentiation syndrome

Question 24

Primary SE to know for selinexor

Answer 24

Hyponatremia